ALL-001 · Acute Lymphoblastic Leukemia · Ph+/Ph- · CAR-T Success Engine

PHASES

SORRIES

NPs

Molecular Engine + Treatment

Tisagenlecleucel Kymriah FDA 2017 PROVEN

CD19 CAR-T. ELIANA: 81% OR pediatric r/r B-ALL. First FDA cancer gene therapy.

Maude 2018 NEJM ELIANA n=75

Blinatumomab BiTE PROVEN

CD19/CD3. CR 39% r/r, MRD conversion 78%. No ex-vivo mfg.

Topp 2015 NEJM

Ph+ ALL TKI Transformation PROVEN

Imatinib/dasatinib+chemo→alloSCT. Transformed prognosis.

Yanada 2006 J Clin Oncol

Inotuzumab (CD22 ADC) PROVEN

CR 80% r/r B-ALL. Rational after CD19 antigen loss.

DeAngelo 2017 Lancet Oncol

Allogeneic Off-the-shelf CAR-T OPEN

CRISPR removes TCR+CD52. UCART19 trial ongoing.

Benjamin 2020 Science Transl Med

Open Sorries — Click to Expand

S-1 SORRY-1 · Antigen-Negative Relapse

S-2 SORRY-2 · CAR-T Exhaustion

S-3 SORRY-3 · CRS Tocilizumab Timing

S-4 SORRY-4 · T-ALL Fratricide Unsolved

S-5 SORRY-5 · MRD Negativity vs Cure

Biomarkers + Signal

See Phases tab for molecular classification details. Key biomarkers noted in phase gates above.

Novel Patterns

Emerging therapies and patterns logged in PEMCLAU v11. See GREYBACK yang case corpus for yin/yang attack-defense mapping.